Latest News - ThromboGenics

Friday, April 21, 2017 | Partnerships, Retina, ThromboGenics

Bicycle Therapeutics Announces a Candidate Preclinical Milestone in Its Ophthalmology Alliance with ThromboGenics

Bicycle Therapeutics announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under it…

Read the full story

Tuesday, January 10, 2017 | Clinical Trials, ThromboGenics

ThromboGenics Enrolls First Patients in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)

ThromboGenics NV announced the enrollment of the first patients in a phase 2, single-masked, multicenter exploratory study evaluating the safety and efficacy of 2 dose levels of THR-317 for the treatm…

Read the full story

Monday, August 08, 2016 | Clinical Trials, Retina, ThromboGenics

ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology

ThromboGenics announced that the results from its 2 Year OASIS phase 3b study with Jetrea (ocriplasmin) have been published in the journal Ophthalmology. The OASIS study was a phase 3b randomized, …

Read the full story

Wednesday, January 13, 2016 | Clinical Trials, Retina, ThromboGenics

ThromboGenics Enrolls First Patient in Phase 2 CIRCLE Trial

ThromboGenics NV announced that the first patient has been enrolled in its phase 2 CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous…

Read the full story

Thursday, November 12, 2015 | Clinical Trials, ThromboGenics

ThromboGenics Announces FDA Acceptance of IND Application for Phase 2 Study with Jetrea for the Treatment of Non-Proliferative Diabetic Retinopathy

ThromboGenics NV announced that the FDA has accepted its investigational new drug (IND) application for its CIRCLE study, a phase 2, randomized, double-masked, sham-controlled, multicenter study…

Read the full story